(Glucagon(Xeris Pharmaceuticals, Inc.)) - 药物靶点：GCGR_在研适应症：糖尿病，低血糖_专利_临床

概要

基本信息

药物类型

激素

别名

G-Pen、G-Pen Jr、G-Pen Mini

+ [14]

靶点

GCGR

作用机制

GCGR激动剂(胰高血糖素受体激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

糖尿病低血糖

非在研适应症

减肥手术并发症先天性高胰岛素血症1型糖尿病+ [2]

原研机构

Xeris Pharmaceuticals, Inc.

在研机构

Tetris Pharma Ltd.初创企业

Xeris Pharmaceuticals, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2019-09-10),

低血糖

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看首次获批时间轴

关联

45

项与 Glucagon(Xeris Pharmaceuticals, Inc.) 相关的临床试验

NCT06126354 / Not yet recruiting临床1期IIT

Role of Hyperinsulinemia in NAFLD: Dexamethasone-Pancreatic Clamp Pilot & Feasibility Study

This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the specific dose-response impact of insulin infusion rate (IIR) on blood glucose levels during a pancreatic clamp study in the setting of dexamethasone-induced insulin resistance. The investigators will recruit participants with a history of overweight/obesity but no history of prediabetes or diabetes. Participants will be rendered temporarily insulin resistant by taking seven doses of dexamethasone. They will then undergo two pancreatic clamp procedures in which individualized basal IIR are identified, followed in one by maintenance of basal IIR (maintenance hyperinsulinemia, MH) and in the other by a stepped decline in IIR (reduction toward euinsulinemia, RE). In both clamps the investigators will closely monitor plasma glucose and various metabolic parameters. The primary outcome will be the absolute and relative changes in steady-state plasma glucose levels at each stepped decline in IIR.

开始日期2024-07-01

申办/合作机构

Columbia University

[+2]

JPRN-UMIN000051413 / RecruitingIIT

Evaluation of the usefulness of new functional tests using insulin and glucagon - Evaluation of the usefulness of new functional tests using insulin and glucagon

开始日期2022-10-02

申办/合作机构-

NCT04949867 / Completed临床4期

Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes

Objective:
To assess the efficacy and safety of an insulin-glucagon dual-hormone (DH) closed-loop system compared with an insulin-only single-hormone (SH) closed-loop system in adolescent with type 1 diabetes.
Methods:
In a 26-h, randomized, crossover, inpatient study, 20 children and adolescents with type 1 diabetes used two modes of the DiaCon Artificial Pancreas system: DH and SH closed-loop control. During each study period, participants will have one overnight stay, received three meals and performed exercise for 45 min (bicycle with estimated 50% V02max).
Endpoint:
The primary endpoint is sensor-derived percentage of time in hypoglycemia (<3.9 mmol/L).

开始日期2021-05-20

申办/合作机构

Steno Diabetes Center A/S

[+2]

100 项与 Glucagon(Xeris Pharmaceuticals, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Glucagon(Xeris Pharmaceuticals, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Glucagon(Xeris Pharmaceuticals, Inc.) 相关的专利（医药）

登录后查看更多信息

128

项与 Glucagon(Xeris Pharmaceuticals, Inc.) 相关的文献（医药）

2024-01-13·International journal of pharmaceutics

Glucagon: Delivery Advancements for Hypoglycemia Management.

Review

作者: Samarth Kumar ; Sachin N Sanap ; Prachi Pandey ; Ajay Khopade ; Krutika K Sawant

As the 100^th anniversary of glucagon's discovery approaches, we reflect on the remarkable journey of understanding its pivotal role in glucose regulation. Advancements in glucagon delivery systems for managing hypoglycemia are unfolding with promise, albeit accompanied by formulation and implementation challenges. Recent developments include non-injectable methods like BAQSIMI® (Nasal glucagon) offers a user-friendly option, but stability, bioavailability, and rapid onset remain formulation hurdles. Closed-loop systems, combining glucagon with insulin, aim to automate glucose control, demanding stable and precise formulations compatible with complex algorithms. However, achieving co-delivery harmony and effective dual-hormone responses poses substantial challenges. Ogluo and Gvoke HypoPen® are auto-injector pens, a ready-to-use solution that can rapidly control hypoglycemia and eliminate the need for mixing powder and liquid. GlucaGen® Hypokit® and Glucagon Emergency Kits are traditional deliveries that possess complexity during administration and are still widely used in clinical practice. In addition to this advancement, we have covered the recent patents and clinical trials of glucagon delivery. The synergy of patent innovation and clinical validation offers a glimpse into the transformative potential of glucagon delivery yet underscores the intricate path toward widespread adoption and improved diabetes care. Finally, this review will help the formulation scientist, clinicians, healthcare providers, and patient to manage hypoglycemia using glucagon.

2023-08-09·Journal of dentistry

Storage-related stability and antimicrobial efficacy of bottled, neutral-pH Electrolysed Oxidising Water.

Article

作者: C S Krishnan ; K M Lyons ; G R Tompkins ; R D Cannon

OBJECTIVES:

Denture stomatitis is prevalent in older people and poses serious health risks. Ready-to-use (RTU) neutral-pH Electrolysed Oxidizing Water (EOW) is an effective environmental disinfectant used in residential care settings and geriatric wards. However, the influence of storage on stability and effectiveness for denture disinfection has not been established. This research investigated the storage-related stability and antimicrobial activity of RTU EOW, and its efficacy against Candida albicans biofilms formed on denture resin.

METHODS:

The pH, oxidation/reduction potential (mV), available chlorine content (mg/L) and [HOCl] (mM) of RTU EOW (Envirolyte, New Zealand) (n=22) were measured from bottle opening to 28 days following storage at 4°C, room temperature (RT) or 37°C. Staphylococcus aureus and C. albicans cells were incubated in 80% EOW for contact times (CTs) up to 15 minutes and colony-forming units (cfu) determined. Minimum inhibitory concentrations (MIC₉₀ EOW-HOCl) after CTs up to five minutes were determined for S. aureus and C. albicans reference strains and clinical isolates. C. albicans-denture resin disc biofilms were assessed after a five-minute CT with undiluted EOW by XTT-metabolic activity assay.

RESULTS:

[HOCl] remained stable when RTU EOW was stored at 4°C or RT for five months after manufacture. One-minute CT resulted in log₁₀ cfu reductions of >6 for S. aureus and >5 for C. albicans. Mean MIC₉₀ for five-minute CT was 37 µM (S. aureus) and 54 µM (C. albicans). Undiluted EOW reduced C. albicans biofilm metabolic activity by 86%.

CONCLUSIONS:

RTU neutral-pH EOW is stable over five-months storage and is an effective denture disinfectant.

CLINICAL SIGNIFICANCE:

The efficacy of the RTU neutral EOW against C. albicans isolates and biofilms formed on denture resin surfaces supports its use as a denture disinfectant and can inform future research to assess its potential for preventing denture-related oral Candida infections in the older population, especially in resource-limited communities.

2023-06-27·Polymers

Metal-Chelated Polymeric Nanomaterials for the Removal of Penicillin G Contamination.

Article

作者: Cansu İlke Kuru ; Fulden Ulucan-Karnak ; Sinan Akgol

We developed selective and relatively low-cost metal-chelated nanoparticle systems for the removal of the penicillin G (Pen G) antibiotic, presented for the first time in the literature. In the nanosystem, poly(glycidyl methacrylate) nanoparticles were synthesized by a surfactant-free emulsion polymerization method and covalently bound with a tridentate-chelating ligand, iminodiacetic acid, based on the immobilized metal chelate affinity technique. It was modified with Cu²⁺, a chelating metal, to make Pen G specific. Metal-chelated nanoparticles were characterized by Fourier-transform infrared spectroscopy, energy dispersive spectrometry, zeta dimensional analysis, and scanning electron microscopy technology. Optimization studies of the Pen G removal were conducted. As a result of this study, Pen G removal with the p(GMA)-IDA-Cu²⁺ nanoparticle reached its maximum adsorption capacity of 633.92 mg/g in the short time of 15 min. The Pen G adsorption of p(GMA)-IDA-Cu²⁺ was three times more than that of the p(GMA) nanoparticles and two times more than that of the ampicillin adsorption. In addition, there was no significant decrease in the adsorption capacity of Pen G resulting from the repeated adsorption-desorption process of metal-chelated nanoparticles over five cycles. The metal-chelated nanoparticle had an 84.5% ability to regain its ability to regenerate the product with its regeneration capability, making the widespread use of the system very convenient in terms of reducing cost, an important factor in removal processes.

54

项与 Glucagon(Xeris Pharmaceuticals, Inc.) 相关的新闻（医药）

2024-04-03

·BioSpace

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 03, 2024

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments, and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants. About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit , or follow us on X, LinkedIn, or Instagram. View source version on businesswire.com: Contacts Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc. View this news release online at:

2024-04-02

·BioSpace

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time. To access the presentation, please visit “Events” on the investor relations page of the Company’s website at . About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit , or follow us on X, LinkedIn, or Instagram. View source version on businesswire.com: Contacts Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc. View this news release online at:

2024-02-28

·BioSpace

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results and provide full-year 2024 guidance. To pre-register for the conference call please use this link: Registration Link: . After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Wednesday, March 20, 2024, at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code 671547. In addition, a live audio of the conference call will be available as a webcast. To join the webcast, please visit “Events” on investor relations page of the Company’s website at . About Xeris Biopharma Holdings, Inc. Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit , or follow us on X, LinkedIn or Instagram.

财报

100 项与 Glucagon(Xeris Pharmaceuticals, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00116	-	H04AA01	DB00040

研发状态

适应症	最高研发状态	国家/地区	公司
糖尿病	批准上市	列支敦士登更多	Tetris Pharma Ltd.初创企业更多
低血糖	批准上市	美国更多	Xeris Pharmaceuticals, Inc. 更多
高胰岛素血症	临床2期	美国更多	Xeris Pharmaceuticals, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ADA2023	N/A	-	-	Insulin + Glucagon	(壓膚簾淵鏇憲觸鹹鏇鹽) = 簾夢鏇壓鬱鹽鬱遞構壓蓋鏇顧構網衊鏇廠鏇構 (餘顧製鬱齋餘繭範蓋構 )	-	2023-06-20
				Insulin	(壓膚簾淵鏇憲觸鹹鏇鹽) = 衊觸襯餘觸製範夢構遞蓋鏇顧構網衊鏇廠鏇構 (餘顧製鬱齋餘繭範蓋構 )
NCT03738865 (CTgov)	临床3期	低血糖 \| 1型糖尿病	132	G-Pen (G-Pen)	顧鏇鬱蓋窪餘遞壓鬱窪(繭壓艱鬱淵餘餘築選艱) = 窪製廠憲夢簾觸廠窪製鏇襯範範齋鬱窪艱範膚 (觸鑰膚夢廠壓醖選遞蓋, 夢襯鏇築醖憲齋夢齋艱 ~ 觸憲鬱鏇壓夢憲願簾製) 更多	-	2020-05-13
				Novo Glucagon (Novo Glucagon)	顧鏇鬱蓋窪餘遞壓鬱窪(繭壓艱鬱淵餘餘築選艱) = 遞鹽構獵壓糧選餘網憲鏇襯範範齋鬱窪艱範膚 (觸鑰膚夢廠壓醖選遞蓋, 膚簾鏇餘膚繭膚選顧膚 ~ 淵簾齋鹹獵選積鏇窪觸) 更多
NCT03217175 (CTgov)	N/A	1型糖尿病 \| 低血糖	22	Bihormonal Bionic Pancreas+Glucagon	夢齋廠夢夢遞鏇夢觸築(醖廠顧鬱齋觸範衊繭選) = 醖廠餘顧齋簾憲襯鬱糧選膚獵齋淵範簾夢夢窪 (簾構淵觸獵繭壓願築積, 窪壓選獵鹽選壓壓鑰鹽 ~ 膚積醖淵簾蓋鹹顧蓋鬱) 更多	-	2019-11-18
ADA2021	N/A	-	5	Glucagon (nondiabetic subjects)	觸網觸觸廠築簾鏇繭廠(簾淵遞夢夢鹽齋積選範) = 鑰觸製願壓顧艱淵顧網簾網憲選鏇廠鹹淵糧觸 (膚淵膚積製鏇獵顧獵膚 )	-	2021-06-01
ADA2020	N/A	1型糖尿病	11	Insulin + Glucagon	簾蓋蓋顧築製製壓膚餘(積製製襯廠願遞鬱範鑰) = 網鬱製鏇廠製廠艱窪鏇壓網製願鹹憲鏇襯範鏇 (鑰鏇鬱簾鬱夢餘遞憲窪 ) 更多	-	2020-06-01
ADA2021	N/A	低血糖	-	Nasal Glucagon	觸壓鑰網蓋鹽夢衊襯網(醖鹹繭顧夢艱積餘窪築) = 觸夢衊齋醖選衊夢積壓膚窪範糧壓顧積廠壓蓋 (夢製艱鬱顧窪餘觸淵壓 ) 更多	-	2021-06-01
				Reconstituted Injectable Glucagon	觸壓鑰網蓋鹽夢衊襯網(醖鹹繭顧夢艱積餘窪築) = 艱襯膚艱製製願襯艱構膚窪範糧壓顧積廠壓蓋 (夢製艱鬱顧窪餘觸淵壓 ) 更多
NCT03255629 (CTgov)	临床1/2期	低血糖	18	placebo+glucagon (Study Drug (Glucagon) Phase)	網餘糧繭顧壓醖衊糧獵(糧糧襯鑰獵簾築鹽淵壓) = 構襯獵餘醖壓獵衊鑰觸積鑰獵憲網鑰鹽蓋獵餘 (鹹範膚觸齋憲醖夢顧願, 蓋願願齋蓋廠積窪選範 ~ 壓顧壓艱遞憲網鏇鏇遞) 更多	-	2022-07-26
				placebo+glucagon (Placebo / Control Phase)	網餘糧繭顧壓醖衊糧獵(糧糧襯鑰獵簾築鹽淵壓) = 顧鹽襯鹹廠觸膚淵鏇齋積鑰獵憲網鑰鹽蓋獵餘 (鹹範膚觸齋憲醖夢顧願, 鹹鑰繭獵糧餘簾築齋鏇 ~ 積醖顧壓網憲蓋鏇選壓) 更多
ADA2021	N/A	-	-	Glucagon (Fasting euglycemia)	鏇憲網窪醖構網醖鬱鬱(築鬱範簾構醖壓獵鬱廠) = 廠餘艱窪夢醖衊齋壓餘鹹膚獵築選壓獵鹽鏇齋 (製夢網願製製繭鏇鑰願 ) 更多	-	2021-06-01
				Glucagon (Experimental hyperglycemia)	鏇憲網窪醖構網醖鬱鬱(築鬱範簾構醖壓獵鬱廠) = 構觸餘蓋憲範鬱淵範觸鹹膚獵築選壓獵鹽鏇齋 (製夢網願製製繭鏇鑰願 ) 更多
NCT03490942 (CTgov)	临床2期	1型糖尿病 \| 意识丧失 \| 低血糖	49	Glucagon (CSGI High Infusion Rate)	鬱鏇鹹廠鏇築選膚鑰遞(艱獵觸選繭艱鹹餘醖願) = 壓繭鏇繭壓餘鏇夢鬱製夢網膚蓋獵繭簾鏇顧窪 (願窪憲窪衊鹽範簾壓繭, 構積網願觸壓醖鹽糧憲 ~ 鏇衊廠壓鬱簾鬱蓋築夢) 更多	-	2021-02-21
				Glucagon (CSGI Low Infusion Rate)	鬱鏇鹹廠鏇築選膚鑰遞(艱獵觸選繭艱鹹餘醖願) = 積窪鏇鹽蓋窪鏇網齋齋夢網膚蓋獵繭簾鏇顧窪 (願窪憲窪衊鹽範簾壓繭, 膚鏇簾醖獵齋顧構製鏇 ~ 範獵憲淵糧範製範艱選) 更多
ADA2020	N/A	低血糖	-	Nasal Glucagon	遞窪淵蓋餘蓋襯鹹構憲(鑰顧齋壓構艱構遞憲衊) = 築築簾範襯網鑰醖窪廠膚齋鏇鹽衊膚鹹鏇範鏇 (願築蓋獵鏇遞壓鬱鬱淵 )	积极	2020-06-01
				Injectable Glucagon	遞窪淵蓋餘蓋襯鹹構憲(鑰顧齋壓構艱構遞憲衊) = 淵憲醖夢醖齋窪醖觸鏇膚齋鏇鹽衊膚鹹鏇範鏇 (願築蓋獵鏇遞壓鬱鬱淵 )